Plant ID: NPO22505
Plant Latin Name: Bombax ceiba
Taxonomy Genus: Bombax
Taxonomy Family: Malvaceae
NCBI TaxonomyDB:
45325
Plant-of-the-World-Online:
n.a.
India
TSHR; NPSR1; | |
BLM; ALPL; RECQL; ALOX12; HSD17B2; HSD17B10; NOX4; POLB; | |
STK3; GSK3B; CAMK2A; JAK3; HCK; CAMKK2; PRKCQ; MET; GRK5; SGK2; MAP4K4; AXL; MARK4; FLT3; CDK1; CSNK1A1; SIK2; ROCK2; TBK1; IKBKE; DYRK1B; FGFR1; JAK2; FLT1; PIM1; PDGFRA; CAMK1D; KDR; CLK2; ROS1; RET; BTK; IGF1R; LRRK2; CDK8; LTK; AURKB; MARK3; ALK; MAPK10; ACVR1; TAOK1; PTK2; PRKX; DYRK1A; MAP3K10; TYRO3; TNK2; MELK; | |
CA2; CA12; CA7; | |
RORC; | |
NR1H4; | |
TYR; | |
AHR; NFKB1; | |
LMNA; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Nuclear hormone receptor subfamily 1 group F | RORC | Nuclear receptor ROR-gamma | P51449 | CHEMBL1741186 |
Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
Protein Kinase | STK3 | Serine/threonine-protein kinase MST2 | Q13188 | CHEMBL4708 |
Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
Protein Kinase | CAMK2A | CaM kinase II alpha | Q9UQM7 | CHEMBL4147 |
Protein Kinase | JAK3 | Tyrosine-protein kinase JAK3 | P52333 | CHEMBL2148 |
Protein Kinase | HCK | Tyrosine-protein kinase HCK | P08631 | CHEMBL3234 |
Protein Kinase | CAMKK2 | CaM-kinase kinase beta | Q96RR4 | CHEMBL5284 |
Protein Kinase | PRKCQ | Protein kinase C theta | Q04759 | CHEMBL3920 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Kinase | GRK5 | G protein-coupled receptor kinase 5 | P34947 | CHEMBL5678 |
Protein Kinase | SGK2 | Serine/threonine-protein kinase Sgk2 | Q9HBY8 | CHEMBL5794 |
Protein Kinase | MAP4K4 | Mitogen-activated protein kinase kinase kinase kinase 4 | O95819 | CHEMBL6166 |
Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
Protein Kinase | MARK4 | MAP/microtubule affinity-regulating kinase 4 | Q96L34 | CHEMBL5754 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
Protein Kinase | CSNK1A1 | Casein kinase I alpha | P48729 | CHEMBL2793 |
Protein Kinase | SIK2 | Serine/threonine-protein kinase SIK2 | Q9H0K1 | CHEMBL5699 |
Protein Kinase | ROCK2 | Rho-associated protein kinase 2 | O75116 | CHEMBL2973 |
Protein Kinase | TBK1 | Serine/threonine-protein kinase TBK1 | Q9UHD2 | CHEMBL5408 |
Protein Kinase | IKBKE | Inhibitor of nuclear factor kappa B kinase epsilon subunit | Q14164 | CHEMBL3529 |
Protein Kinase | DYRK1B | Dual specificity tyrosine-phosphorylation-regulated kinase 1B | Q9Y463 | CHEMBL5543 |
Protein Kinase | FGFR1 | Fibroblast growth factor receptor 1 | P11362 | CHEMBL3650 |
Protein Kinase | JAK2 | Tyrosine-protein kinase JAK2 | O60674 | CHEMBL2971 |
Protein Kinase | FLT1 | Vascular endothelial growth factor receptor 1 | P17948 | CHEMBL1868 |
Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
Protein Kinase | PDGFRA | Platelet-derived growth factor receptor alpha | P16234 | CHEMBL2007 |
Protein Kinase | CAMK1D | CaM kinase I delta | Q8IU85 | CHEMBL5073 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | CLK2 | Dual specificity protein kinase CLK2 | P49760 | CHEMBL4225 |
Protein Kinase | ROS1 | Proto-oncogene tyrosine-protein kinase ROS | P08922 | CHEMBL5568 |
Protein Kinase | RET | Tyrosine-protein kinase receptor RET | P07949 | CHEMBL2041 |
Protein Kinase | BTK | Tyrosine-protein kinase BTK | Q06187 | CHEMBL5251 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | LRRK2 | Leucine-rich repeat serine/threonine-protein kinase 2 | Q5S007 | CHEMBL1075104 |
Protein Kinase | CDK8 | Cell division protein kinase 8 | P49336 | CHEMBL5719 |
Protein Kinase | LTK | Leukocyte tyrosine kinase receptor | P29376 | CHEMBL5627 |
Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
Protein Kinase | MARK3 | Serine/threonine-protein kinase c-TAK1 | P27448 | CHEMBL5600 |
Protein Kinase | ALK | ALK tyrosine kinase receptor | Q9UM73 | CHEMBL4247 |
Protein Kinase | MAPK10 | c-Jun N-terminal kinase 3 | P53779 | CHEMBL2637 |
Protein Kinase | ACVR1 | Activin receptor type-1 | Q04771 | CHEMBL5903 |
Protein Kinase | TAOK1 | Serine/threonine-protein kinase TAO1 | Q7L7X3 | CHEMBL5261 |
Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
Protein Kinase | PRKX | Serine/threonine-protein kinase PRKX | P51817 | CHEMBL5818 |
Protein Kinase | DYRK1A | Dual-specificity tyrosine-phosphorylation regulated kinase 1A | Q13627 | CHEMBL2292 |
Protein Kinase | MAP3K10 | Mitogen-activated protein kinase kinase kinase 10 | Q02779 | CHEMBL2873 |
Protein Kinase | TYRO3 | Tyrosine-protein kinase receptor TYRO3 | Q06418 | CHEMBL5314 |
Protein Kinase | TNK2 | Tyrosine kinase non-receptor protein 2 | Q07912 | CHEMBL4599 |
Protein Kinase | MELK | Maternal embryonic leucine zipper kinase | Q14680 | CHEMBL4578 |
Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0003824; catalytic activity | GO:0004715; non-membrane spanning protein tyrosine kinase activity | 1.399E-11 | 3.275E-09 | BTK, DYRK1A, HCK, JAK2, JAK3, MELK, PTK2, TNK2 |
MF | GO:0003824; catalytic activity | GO:0004712; protein serine/threonine/tyrosine kinase activity | 1.803E-10 | 3.505E-08 | AURKB, CLK2, DYRK1A, DYRK1B, LRRK2, MAPK10, TNK2 |
BP | GO:0040011; locomotion | GO:0030335; positive regulation of cell migration | 7.838E-10 | 1.323E-07 | ACVR1, ALOX12, CAMK1D, FGFR1, FLT1, IGF1R, JAK2, KDR, MET, NOX4, PDGFRA, PTK2, RET, ROCK2 |
BP | GO:0009987; cellular process | GO:0014068; positive regulation of phosphatidylinositol 3-kinase signaling | 4.848E-09 | 7.434E-07 | FGFR1, FLT1, FLT3, JAK2, KDR, PDGFRA, PTK2 |
MF | GO:0060089; molecular transducer activity | GO:0005021; vascular endothelial growth factor-activated receptor activity | 6.157E-09 | 9.311E-07 | FLT1, FLT3, KDR, PDGFRA |
BP | GO:0009987; cellular process | GO:0038084; vascular endothelial growth factor signaling pathway | 2.348E-07 | 2.972E-05 | FLT1, FLT3, KDR, PDGFRA |
CC | GO:0044464; cell part | GO:0031234; extrinsic component of cytoplasmic side of plasma membrane | 2.791E-07 | 3.512E-05 | BTK, HCK, JAK2, JAK3, PTK2, TNK2 |
BP | GO:0050896; response to stimulus | GO:0006954; inflammatory response | 5.853E-07 | 6.890E-05 | ACVR1, AXL, CAMK1D, HCK, JAK3, NFKB1, NOX4, NR1H4, POLB, PRKCQ, TBK1 |
BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 6.815E-07 | 7.894E-05 | ALPL, BLM, CYP1A1, CYP1B1, FLT3, LRRK2, NFKB1, NOX4, ROCK2, RORC |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 6.798E-07 | 7.894E-05 | CYP1A1, CYP1A2, CYP1B1, CYP3A4, NOX4 |
MF | GO:0005488; binding | GO:0005524; ATP binding | 8.064E-41 | 2.195E-37 | ACVR1, ALK, AURKB, AXL, BLM, BTK, CAMK1D, CAMK2A, CAMKK2, CDK1, CDK8, CLK2, CSNK1A1, DYRK1A, DYRK1B, FGFR1, FLT1, FLT3, GRK5, GSK3B, HCK, IGF1R, IKBKE, JAK2, JAK3, KDR, LRRK2, LTK, MAP3K10, MAP4K4, MAPK10, MARK3, MARK4, MELK, MET, PDGFRA, PIM1, PRKCQ, PRKX, PTK2, RECQL, RET, ROCK2, ROS1, SGK2, SIK2, STK3, TAOK1, TBK1, TNK2, TYRO3 |
BP | GO:0048511; rhythmic process | GO:0048511; rhythmic process | 1.071E-06 | 1.215E-04 | AHR, AXL, DYRK1A, GSK3B, MAPK10, PDGFRA, ROCK2, RORC, TYRO3 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.489E-06 | 1.663E-04 | CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 1.562E-06 | 1.735E-04 | AXL, FGFR1, MET, NOX4, PDGFRA, PTK2, STK3 |
MF | Unclassified; | GO:0004872; receptor activity | 2.732E-06 | 2.931E-04 | ACVR1, AHR, ALK, AXL, FGFR1, FLT1, FLT3, IGF1R, KDR, LTK, MET, NPSR1, NR1H4, PDGFRA, RET, RORC, ROS1, TSHR, TYRO3 |
BP | GO:0050896; response to stimulus | GO:0034614; cellular response to reactive oxygen species | 3.076E-06 | 3.267E-04 | AXL, BTK, CAMKK2, CDK1, CYP1B1, PDGFRA |
MF | GO:0005488; binding | GO:0043548; phosphatidylinositol 3-kinase binding | 3.927E-06 | 4.053E-04 | AXL, IGF1R, JAK2, TYRO3 |
MF | GO:0098772; molecular function regulator | GO:0005088; Ras guanyl-nucleotide exchange factor activity | 4.004E-06 | 4.106E-04 | CAMK2A, FGFR1, JAK2, JAK3, MET, PDGFRA, PTK2, RET |
CC | GO:0044464; cell part | GO:0005737; cytoplasm | 4.146E-06 | 4.219E-04 | AHR, ALOX12, BLM, BTK, CA2, CAMK1D, CAMK2A, CAMKK2, CYP3A4, GRK5, GSK3B, HSD17B10, IKBKE, JAK2, LRRK2, MAP3K10, MAP4K4, MAPK10, MELK, NFKB1, NPSR1, PDGFRA, PIM1, POLB, PRKX, PTK2, RECQL, SIK2, STK3, TAOK1, TBK1, TNK2, TYR |
BP | GO:0008152; metabolic process | GO:0043552; positive regulation of phosphatidylinositol 3-kinase activity | 4.519E-06 | 4.555E-04 | FLT1, FLT3, PDGFRA, PTK2 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 5.848E-06 | 5.815E-04 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 7.201E-06 | 7.000E-04 | AXL, FLT1, KDR, PTK2, ROCK2 |
MF | GO:0005488; binding | GO:0020037; heme binding | 8.222E-06 | 7.887E-04 | CYP1A1, CYP1A2, CYP1B1, CYP3A4, JAK2, NOX4 |
MF | GO:0005488; binding | GO:0019838; growth factor binding | 8.987E-06 | 8.583E-04 | ACVR1, FGFR1, FLT1, IGF1R, KDR, PDGFRA |
BP | GO:0051179; localization | GO:0033160; positive regulation of protein import into nucleus, translocation | 1.066E-05 | 9.967E-04 | CDK1, JAK2, LRRK2 |
BP | GO:0009987; cellular process | GO:2001028; positive regulation of endothelial cell chemotaxis | 1.383E-05 | 1.244E-03 | FGFR1, KDR, MET |
BP | GO:0009987; cellular process | GO:0043065; positive regulation of apoptotic process | 1.452E-05 | 1.296E-03 | CAMK1D, CAMK2A, CYP1B1, GSK3B, JAK2, LTK, MAP3K10, MELK, NOX4, RET, STK3 |
BP | GO:0065007; biological regulation | GO:0000187; activation of MAPK activity | 1.549E-05 | 1.375E-03 | ALK, CDK1, LRRK2, MAP3K10, MAPK10, TAOK1 |
CC | GO:0044464; cell part | GO:0005829; cytosol | 1.554E-05 | 1.375E-03 | AHR, ALOX12, AURKB, BLM, BTK, CA2, CA7, CAMK2A, CAMKK2, CDK1, CSNK1A1, FGFR1, FLT3, GRK5, GSK3B, HCK, IKBKE, JAK2, JAK3, LMNA, LRRK2, MAPK10, MARK3, MARK4, NFKB1, PIM1, PRKCQ, PTK2, RET, ROCK2, SGK2, STK3, TAOK1, TBK1, TYR |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.188E-05 | 1.876E-03 | CA12, CA2, CA7 |
CC | GO:0043226; organelle | GO:0005634; nucleus | 2.411E-05 | 2.059E-03 | AHR, AURKB, BLM, BTK, CAMK1D, CAMK2A, CAMKK2, CDK1, CDK8, CLK2, DYRK1A, DYRK1B, FLT3, GSK3B, IKBKE, JAK2, KDR, LMNA, LRRK2, MAPK10, MELK, NFKB1, NOX4, PDGFRA, PIM1, POLB, PRKX, PTK2, RECQL, ROCK2, RORC, SIK2, STK3, TNK2, TYR, TYRO3 |
BP | GO:0009987; cellular process | GO:0008631; intrinsic apoptotic signaling pathway in response to oxidative stress | 3.252E-05 | 2.693E-03 | CYP1B1, JAK2, MELK |
MF | GO:0003824; catalytic activity | GO:0035173; histone kinase activity | 3.252E-05 | 2.693E-03 | AURKB, CDK1, JAK2 |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 4.101E-05 | 3.303E-03 | CA2, CA7 |
MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 4.101E-05 | 3.303E-03 | CYP1A1, CYP3A4 |
BP | GO:0032502; developmental process | GO:0001525; angiogenesis | 4.679E-05 | 3.615E-03 | CYP1B1, FGFR1, FLT1, KDR, PDGFRA, PRKX, PTK2 |
BP | GO:0008152; metabolic process | GO:0045740; positive regulation of DNA replication | 5.242E-05 | 4.005E-03 | CDK1, FGFR1, IGF1R, PDGFRA |
BP | GO:0009987; cellular process | GO:0071396; cellular response to lipid | 5.273E-05 | 4.015E-03 | AXL, FLT3, LTK, NFKB1, NR1H4, RET, ROCK2, RORC |
BP | GO:0050896; response to stimulus | GO:0010035; response to inorganic substance | 5.306E-05 | 4.026E-03 | AXL, BLM, CA2, CDK1, CYP1A1, CYP1A2, CYP1B1, KDR, LRRK2 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 6.294E-05 | 4.709E-03 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0050896; response to stimulus | GO:0032496; response to lipopolysaccharide | 7.687E-05 | 5.617E-03 | ALPL, AXL, CYP1A1, CYP1A2, JAK2, NFKB1, NR1H4 |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 8.181E-05 | 5.822E-03 | CYP1A1, CYP1A2 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 8.181E-05 | 5.822E-03 | CYP1A2, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 8.336E-05 | 5.912E-03 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0009987; cellular process | GO:0097237; cellular response to toxic substance | 8.541E-05 | 5.999E-03 | AXL, CDK1, CYP1B1, KDR, NFKB1 |
BP | GO:0009987; cellular process | GO:0035690; cellular response to drug | 8.596E-05 | 6.019E-03 | AXL, BLM, CDK1, CYP1B1, KDR, LRRK2, NFKB1 |
BP | GO:0009987; cellular process | GO:0010638; positive regulation of organelle organization | 9.138E-05 | 6.337E-03 | AURKB, CAMKK2, GSK3B, HCK, KDR, LRRK2, MET, NOX4, PRKCQ, ROCK2 |
BP | GO:0009987; cellular process | GO:0009968; negative regulation of signal transduction | 1.066E-04 | 7.231E-03 | ACVR1, CSNK1A1, DYRK1A, GSK3B, IGF1R, LMNA, LRRK2, MARK3, MET, NR1H4, PDGFRA, PRKCQ, STK3, TYRO3 |
BP | GO:0050896; response to stimulus | GO:0071417; cellular response to organonitrogen compound | 1.088E-04 | 7.311E-03 | BLM, GSK3B, IGF1R, LRRK2, NFKB1, NOX4, NR1H4, TSHR |
BP | GO:0032502; developmental process | GO:0045597; positive regulation of cell differentiation | 1.108E-04 | 7.424E-03 | ACVR1, AXL, BTK, CA2, CAMK1D, FGFR1, JAK2, KDR, LTK, NFKB1, RET, STK3 |
MF | GO:0003824; catalytic activity | GO:0009378; four-way junction helicase activity | 1.360E-04 | 8.827E-03 | BLM, RECQL |
MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 1.360E-04 | 8.827E-03 | CYP1A1, CYP3A4 |
BP | GO:0009987; cellular process | GO:0080135; regulation of cellular response to stress | 1.420E-04 | 9.173E-03 | CAMK2A, DYRK1A, GSK3B, IGF1R, LRRK2, MAP3K10, MAP4K4, MET, STK3, TAOK1 |
BP | GO:0008152; metabolic process | GO:0016572; histone phosphorylation | 1.521E-04 | 9.716E-03 | AURKB, CDK1, JAK2 |
BP | GO:0008152; metabolic process | GO:0018105; peptidyl-serine phosphorylation | 3.738E-17 | 1.596E-14 | AURKB, CAMK1D, CAMK2A, CAMKK2, CDK1, CSNK1A1, DYRK1A, GSK3B, IKBKE, LRRK2, MAP3K10, PRKCQ, PRKX, SGK2, TBK1 |
BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 1.007E-13 | 3.225E-11 | BTK, HCK, IGF1R, JAK2, JAK3, KDR, PTK2, ROS1, TNK2 |
BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 2.782E-13 | 8.185E-11 | ACVR1, CAMK1D, CAMK2A, CAMKK2, CDK1, DYRK1A, GSK3B, LRRK2, MAP3K10, TBK1 |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 3.057E-09 | 4.829E-07 | PDGFRA, GSK3B, FLT1, KDR, JAK2, SGK2, JAK3, MET, PTK2, NFKB1, FGFR1, IGF1R |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 4.495E-08 | 3.551E-06 | MAPK10, PDGFRA, GSK3B, FLT1, ROCK2, KDR, MET, PTK2, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 1.676E-07 | 6.620E-06 | RET, MAPK10, PDGFRA, GSK3B, ROCK2, FLT3, MET, NFKB1, PTK2, FGFR1, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 1.221E-07 | 6.429E-06 | MAPK10, PDGFRA, TBK1, FLT1, KDR, MET, NFKB1, FGFR1, IGF1R |
09150 Organismal Systems | 09151 Immune system | hsa04062 | Chemokine signaling pathway | 3.610E-07 | 1.141E-05 | GSK3B, HCK, GRK5, ROCK2, JAK2, JAK3, NFKB1, PTK2 |
09160 Human Diseases | 09167 Infectious diseases | hsa05162 | Measles | 5.868E-07 | 1.545E-05 | GSK3B, TBK1, PRKCQ, JAK2, JAK3, IKBKE, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 8.435E-06 | 1.333E-04 | ROCK2, CAMK2A, KDR, MET, PTK2, FGFR1, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 4.264E-06 | 8.421E-05 | RET, PDGFRA, FLT3, MET, FGFR1 |
09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 2.074E-06 | 4.682E-05 | CYP1A2, HSD17B2, CYP1A1, CYP1B1, CYP3A4 |
09150 Organismal Systems | 09152 Endocrine system | hsa04920 | Adipocytokine signaling pathway | 5.299E-06 | 9.302E-05 | MAPK10, PRKCQ, JAK2, NFKB1, CAMKK2 |
09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 1.723E-05 | 2.269E-04 | PDGFRA, GSK3B, NFKB1, FGFR1, IGF1R |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 1.225E-05 | 1.759E-04 | ACVR1, GSK3B, JAK2, JAK3, FGFR1, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04010 | MAPK signaling pathway | 3.668E-05 | 3.764E-04 | MAPK10, PDGFRA, TAOK1, NFKB1, MAP4K4, FGFR1, STK3 |
09160 Human Diseases | 09167 Infectious diseases | hsa05164 | Influenza A | 3.989E-05 | 3.764E-04 | MAPK10, GSK3B, TBK1, JAK2, IKBKE, NFKB1 |
09140 Cellular Processes | 09141 Transport and catabolism | hsa04144 | Endocytosis | 4.050E-05 | 3.764E-04 | RET, PDGFRA, FLT1, GRK5, KDR, MET, IGF1R |
09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 3.137E-05 | 3.540E-04 | HSD17B2, CYP1A1, CYP1B1, IGF1R |
09160 Human Diseases | 09167 Infectious diseases | hsa05169 | Epstein-Barr virus infection | 8.846E-05 | 6.988E-04 | MAPK10, GSK3B, TBK1, CDK1, JAK3, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 4.669E-05 | 4.098E-04 | FLT1, FLT3, MET, NFKB1, PTK2, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 1.124E-04 | 8.126E-04 | PDGFRA, FLT1, KDR, MET, FGFR1, IGF1R |
09160 Human Diseases | 09167 Infectious diseases | hsa05168 | Herpes simplex infection | 5.439E-05 | 4.523E-04 | MAPK10, TBK1, CDK1, JAK2, IKBKE, NFKB1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05160 | Hepatitis C | 1.181E-04 | 8.126E-04 | MAPK10, GSK3B, TBK1, IKBKE, NFKB1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04310 | Wnt signaling pathway | 1.605E-04 | 9.394E-04 | MAPK10, GSK3B, ROCK2, CSNK1A1, CAMK2A |
09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 1.250E-04 | 8.230E-04 | PDGFRA, MET, FGFR1, IGF1R |
09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 1.320E-04 | 8.343E-04 | MAPK10, GSK3B, JAK2, NFKB1 |
09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04060 | Cytokine-cytokine receptor interaction | 3.844E-04 | 2.024E-03 | ACVR1, PDGFRA, FLT1, FLT3, KDR, MET |
09150 Organismal Systems | 09151 Immune system | hsa04622 | RIG-I-like receptor signaling pathway | 1.183E-04 | 8.126E-04 | MAPK10, TBK1, IKBKE, NFKB1 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 1.393E-04 | 8.465E-04 | CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04012 | ErbB signaling pathway | 2.743E-04 | 1.494E-03 | MAPK10, GSK3B, CAMK2A, PTK2 |
09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 4.844E-04 | 2.319E-03 | MAPK10, PIM1, JAK2, NFKB1 |
09150 Organismal Systems | 09157 Sensory system | hsa04750 | Inflammatory mediator regulation of TRP channels | 4.320E-04 | 2.133E-03 | MAPK10, CAMK2A, PRKCQ, ALOX12 |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 2.184E-04 | 1.233E-03 | CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 7.560E-04 | 3.229E-03 | MAPK10, ROCK2, CAMK2A, NFKB1, TSHR |
09150 Organismal Systems | 09151 Immune system | hsa04620 | Toll-like receptor signaling pathway | 5.814E-04 | 2.625E-03 | MAPK10, TBK1, IKBKE, NFKB1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 5.217E-04 | 2.424E-03 | FLT1, CAMK2A, NFKB1, IGF1R |
09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04931 | Insulin resistance | 6.459E-04 | 2.835E-03 | MAPK10, GSK3B, PRKCQ, NFKB1 |
09150 Organismal Systems | 09156 Nervous system | hsa04722 | Neurotrophin signaling pathway | 9.257E-04 | 3.849E-03 | MAPK10, GSK3B, CAMK2A, NFKB1 |
09150 Organismal Systems | 09158 Development | hsa04360 | Axon guidance | 1.143E-03 | 4.514E-03 | GSK3B, ROCK2, MET, PTK2 |
09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 1.908E-03 | 6.555E-03 | MAPK10, TBK1, IKBKE, NFKB1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05166 | HTLV-I infection | 2.380E-03 | 7.631E-03 | POLB, PDGFRA, GSK3B, JAK3, NFKB1 |
09150 Organismal Systems | 09152 Endocrine system | hsa04921 | Oxytocin signaling pathway | 2.542E-03 | 7.876E-03 | CAMK1D, ROCK2, CAMK2A, CAMKK2 |
09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 1.139E-03 | 4.514E-03 | FLT3, PIM1, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 1.665E-03 | 5.980E-03 | PDGFRA, CAMK2A, IGF1R |
09150 Organismal Systems | 09151 Immune system | hsa04662 | B cell receptor signaling pathway | 2.323E-03 | 7.631E-03 | GSK3B, BTK, NFKB1 |
09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 2.934E-05 | 3.540E-04 | CA12, CA2, CA7 |
09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 1.665E-03 | 5.980E-03 | CYP1A2, CYP1A1, CYP3A4 |
09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 4.017E-04 | 2.047E-03 | CYP1A2, CYP1A1, CYP1B1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 1.896E-03 | 6.555E-03 | MAPK10, MET, NFKB1 |
09150 Organismal Systems | 09151 Immune system | hsa04623 | Cytosolic DNA-sensing pathway | 1.592E-03 | 5.980E-03 | TBK1, IKBKE, NFKB1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05131 | Shigellosis | 1.665E-03 | 5.980E-03 | MAPK10, ROCK2, NFKB1 |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 2.415E-03 | 7.631E-03 | MET, FGFR1, IGF1R |
09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 2.146E-03 | 7.213E-03 | CA2, NR1H4, CYP3A4 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
C00-D49: Neoplasms | Lymphoma | C81-C86 | FGFR1; |
H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | FLT1; |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; FLT1; |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; PDGFRA; |
C00-D49: Neoplasms | Endometrial cancer | C54.1 | FGFR1; |
NA: NA | Edema | NA | CA2; |
C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | IKBKE; |
I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | FLT1; |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | FGFR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | GSK3B; |
C00-D49: Neoplasms | Bladder cancer | C67 | FLT1; |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
C00-D49: Neoplasms | Breast cancer | C50 | CDK1; IGF1R; KDR; FLT3; JAK2; |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; PDGFRA; |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
C00-D49: Neoplasms | Melanoma | C43 | KDR; TYR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR; |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
C00-D49: Neoplasms | Glioma | C71 | KDR; |
C00-D49: Neoplasms | Glioblastoma multiforme | C71 | PDGFRA; |
L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | FLT1; |
C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; |
P00-P96: Certain conditions originating in the perinatal period | Central nervous system injury | P11.9 | MAPK10; |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PTK2; |
C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; JAK2; |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | RET; |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
C00-D49: Neoplasms | Osteosarcoma | C40-C41 | GSK3B; |
C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; TSHR; RET; |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; JAK2; |
I00-I99: Diseases of the circulatory system | Hereditary hemorrhagic telangiectasia | I78.0 | FLT1; |
C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; FLT1; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CDK1; IGF1R; |
C00-D49: Neoplasms | CLL | NA | FLT3; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PRKCQ; |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
NA: NA | GIST | NA | FLT3; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
C00-D49: Neoplasms | Myeloproliferative disorder | C94.6 | JAK2; |
NA: NA | Myeloproliferative neoplasm | NA | JAK2; |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
C00-D49: Neoplasms | Mesothelioma | C45 | PTK2; MARK3; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; |
C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; |
H00-H59: Diseases of the eye and adnexa | Exudative age-related macular degeneration | H35.3 | FLT1; |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
C00-D49: Neoplasms | Renal cancer | C64 | KDR; FLT1; |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; PDGFRA; |
NA: NA | HIV infections | NA | AHR; |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
I00-I99: Diseases of the circulatory system | Peripheral arterial occlusive disease | I73.9 | FGFR1; |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Renal transplantation | D89.8 | JAK2; |
C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
I00-I99: Diseases of the circulatory system | Severe coronary heart disease | I25.1 | FGFR1; |
C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3; ALPL; |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
C00-D49: Neoplasms | Soft tissue sarcoma | C00-D49 | PDGFRA; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; AURKB; PTK2; IGF1R; KDR; FGFR1; FLT3; PDGFRA; MELK; RET; ROS1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CAMK2A; ROCK2; TYR; |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; AHR; JAK2; |
G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | JAK2; |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; CAMK2A; |
A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL; |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
H00-H59: Diseases of the eye and adnexa | Neovascular age-related macular degeneration | H35.3 | FLT1; |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Anemia | D50-D64 | JAK2; |
C00-D49: Neoplasms | Cancer | C00-C96 | PIM1; MET; CDK1; PTK2; IGF1R; KDR; FGFR1; NFKB1; FLT3; FLT1; TNK2; JAK2; RET; GSK3B; |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; |
C00-D49: Neoplasms | Polycythemia vera | D45 | JAK2; |
I00-I99: Diseases of the circulatory system | Peripheral vascular disease | I73.9 | FLT1; |
C00-D49: Neoplasms | ALK-positive advanced or metastatic NSCLC | C33, C34 | ROS1; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | GSK3B; |